DIABETIC MACULAR EDEMA (DME)

This study tests a new medicine called EYE103, given as an eye injection, for people with diabetic macular edema (DME) — a condition that causes vision loss in people with diabetes. About 1,054 adults with DME will receive either EYE103 or an existing drug (ranibizumab) every 4 w…

This study compares two common eye injections, aflibercept and bevacizumab, in 116 adults aged 30-60 with diabetic macular edema (fluid buildup in the retina causing vision loss). Participants receive monthly injections for 2 months, and doctors measure vision improvement and ret…

This study tests whether KHK4951 eye drops can improve vision in people with diabetic macular edema (DME), a condition where fluid builds up in the eye due to diabetes. About 150 adults with DME will use the eye drops daily for several months. The goal is to see if the drops can …

This early-stage study tests a new drug called EYE201, given as three eye injections over 12 weeks, for people with vision loss due to swelling in the back of the eye. The study includes patients with three different eye conditions: branch retinal vein occlusion, diabetic macular…

This early-phase study tests a single injection of avoralstat into the eye for people with diabetic macular edema, a condition that causes vision loss. Nine adults with diabetes and center-involved swelling in the retina will be monitored for safety and any signs of improvement i…

This study compares a new numbing eye gel (IHEEZO) to standard numbing drops plus a shot for people getting eye injections for conditions like macular degeneration. About 236 adults will receive one of the two numbing methods before their injection. The goal is to see if the gel …

This study looks at how aflibercept 8 mg, a drug injected into the eye, is used in routine care for people with age-related macular degeneration or diabetic macular edema in Japan. Researchers will analyze existing health records from about 3000 patients to understand who gets th…